We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Apenas manchetes de alto sinal — eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Bristol-Myers Squibb has had an impressive run over the past six months as its shares have beaten the S&P 500 by 5.7%. The stock now trades at $55.77, marking a 13.6% gain. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
RDY stock down 5% on missing fiscal fourth-quarter 2026 earnings and revenue estimates as North America generics sales slumped.
Xenon Pharmaceuticals (NASDAQ:XENE) said it is preparing to submit a new drug application to the U.S. Food and Drug Administration in the third quarter of 2026 for azetukalner, its investigational anti-seizure medicine, after reporting positive Phase 3 data in focal onset seizures during the first q
PRTA posted a Q1 profit as a $50M Novo Nordisk milestone payment boosted revenue and improved its 2026 cash outlook.
Bristol-Myers Squibb, NYSE:BMY, has launched a new patient-focused "Won't Lose" media campaign ahead of the FIFA World Cup 2026. The campaign highlights the company’s focus on breakthrough medicines and resilience in the fight against serious diseases. The initiative is set to run nationwide across digital and social platforms and will feature high profile sports personalities. Bristol-Myers Squibb, NYSE:BMY, is putting fresh attention on its brand with "Won't Lose," a broad media effort...
Cytokinetics posts Q1 loss as Myqorzo launch lifts revenues to $19.4M, signaling commercial shift amid rising SG&A tied to rollout and expansion.